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Background: The current challenge in NSCLC is to optimize avail-
able therapeutic strategies by incorporating new agents into existing 
treatment regimens. Strategies that target key signaling pathways offer 
great potential and two validated therapeutic targets are VEGF and 
EGF and their receptors. To study the potential therapeutic efﬁcacy of 
lung cancer treatments we have developed orthotopic lung adenocar-
cinoma models that mimic clinical patterns of NSCLC growth, which 
are sensitive (H441) or highly resistant (PC14) to EGFR inhibition. 
EGFR is expressed in both models, though EGFR ligand expression 
(TGF-α/EGF) was observed only for the H441 lung adenocarcinomas 
and was associated with resultant endothelial expression and activation 
of EGFR. 
Methods: Human lung adenocarcinoma cells (PC14 or H441) were 
injected into the left lungs of nude mice with lung tumors evident 
within 14 days. Tumor-bearing mice (10/group) were treated with (A) 
AZD2171 (RECENTIN™), a highly potent and selective inhibitor 
of VEGFR-1, -2, and -3 (6 mg/kg/day orally); (B) vandetanib (ZAC-
TIMA™), a selective inhibitor of VEGFR-2 and EGFR (25 mg/kg/day 
orally); (C) AZD2171 plus paclitaxel (200 µg/week ip); (D) vandetanib 
plus paclitaxel; (E) geﬁtinib (IRESSA™), a highly selective inhibitor 
of EGFR (25 or 75 mg/kg/day orally); (F) geﬁtinib plus AZD2171; or 
(G) appropriate drug vehicles as controls. All animals were then sac-
riﬁced and assessed for tumor burden, pleural effusion and lymphatic 
metastasis. Tumor tissues were then subjected to immunohistochemical 
analyses. 
Results: Vandetanib or AZD2171 treatment substantially reduced lung 
tumor burden in both the H441 and PC14 tumor models, and prevented 
mediastinal adenopathy and pleural effusion relative to controls. In 
both models, the antitumor and antimetastatic effects of AZD2171 and 
vandetanib were markedly enhanced when they were combined with 
paclitaxel. Immunohistochemical analyses of H441 lung adenocarci-
noma revealed that tumor and endothelial cell VEGFR activation was 
inhibited by vandetanib or AZD2171 therapy alone and in combination 
with paclitaxel in lung tumors. Vandetanib or AZD2171 inhibited tumor 
angiogenesis and enhanced the antivascular and antitumor effects of 
paclitaxel. H441 tumors, but not PC14 tumors, were sensitive to EGFR 
signaling inhibition by geﬁtinib, which enhanced the antitumor and 
antivascular effects of AZD2171 in a dose-dependent fashion for H441 
lung adenocarcinomas. Immunohistochemical evaluation of H441 
lung adenocarcinomas showed that angiogenesis, tumor cell prolifera-
tion, and expression of proangiogenic and invasive molecules were 
substantially reduced by treatment with AZD2171 in combination with 
geﬁtinib compared with either agent alone.
Conclusions: These studies demonstrate that VEGFR signaling inhibi-
tion by AZD2171 or vandetanib inhibits tumor growth and angiogen-
esis in orthotopic human lung adenocarcinoma models. The antitumor 
and antivascular effects of AZD2171 or vandetanib were substantially 
enhanced when they were combined with paclitaxel. EGFR signal-
ing inhibition enhanced the therapeutic efﬁcacy of VEGFR signaling 
inhibition for H441 lung tumors, which express both EGFR and its 
ligand(s). These ﬁndings provide mechanistic insights into the biology 
underlying the beneﬁcial combination of AZD2171 or vandetanib with 
paclitaxel in lung cancer, and suggest that a customized approach for 
combined EGFR and VEGFR signaling inhibition based upon EGFR 
expression and activation in lung tumors and endothelial cells warrants 
further investigation.
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Background: Both epidermal growth factor receptor (EGFR) mutation 
and gene copy number of HER2, a member of EGFR family, are as-
sociated with geﬁtinib sensitivity. We carried out a correlative study to 
determine the relationships between EGFR mutations, EGFR or HER2 
protein expressions, their activation status (pEGFR, pHER2) or insulin-
like growth factor receptor 1 (IGFR-1) protein expressions and clinical 
outcomes after geﬁtinib treatment in advanced NSCLC. 
Method: Tumors from patients (pts) were evaluated for EGFR muta-
tions by DNA sequence, and for protein expressions of EGFR, pEGFR, 
HER2, pHER2 and IGFR-1 by immunohistochemistry. Time to 
progression (TTP) was calculated by the Kaplan-Meier method; groups 
were compared using the log-rank test. Risk factors associated with 
TTP were evaluated with Cox proportional hazard regression modeling. 
Correlation between EGFR mutation and response was evaluated by 
Fisher’s direct method. Relationship between each protein expression 
and response was tested by two-sided. Primary endpoint was to detect 
biomarkers to predict geﬁtinib sensitivity. 
Results: From Dec. 2003 to Dec. 2005, 103 consecutive pts were 
enrolled onto the study, and received geﬁtinib until disease progres-
sion. Median age was 68 years, female (58%), adenocarcinoma (83%), 
never smoker (55%) and no previous chemotherapy (49%). 98 pts were 
evaluable for efﬁcacies, toxicities and gene analyses. Forty-one pts 
(42%) had EGFR mutations; 14 pts had deletional mutation in exon 
19, 27 pts had missense mutation (L858R) in exon 21. EGFR muta-
tions were signiﬁcantly related to response (62 vs. 26%; P = 0.001), 
disease control rate (92 vs. 65%; P = 0.003) and TTP (median, 10.1 
vs. 5.1months; hazard ratio = 0.64; P = 0.048). Both pEGFR (0, +1 vs. 
